Skip to main content
OpenTrials

Clinical trial condition

Recurrent B Acute Lymphoblastic Leukemia

Explore clinical trials studying Recurrent B Acute Lymphoblastic Leukemia. Study availability and eligibility vary by location and protocol.

16 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Recurrent B Acute Lymphoblastic Leukemia trial results

Active, Not Recruiting

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 157 locations
View Trial Details
Active, Not Recruiting

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

NCT03504644

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 170 locations
View Trial Details
Active, Not Recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +15 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 186 locations
View Trial Details
Active, Not Recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
Locations
  • Yale University New Haven, Connecticut, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions